Key result
Anisodamine treatment in patients with septic shock was associated with an 8.3% incidence of arrhythmias compared to 10.3% in the control group (p=0.627).
Why the study?
The potential beneficial effects of anisodamine on microcirculation in septic shock have been described, but its numerous cardiac side effects have not been adequately addressed.
Answers are grounded in this paper and cite their sources.
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. With great interest, we read the recently published metaanalysis by Yu et al. stating that anisodamine was able to improve microcirculation in patients with septic shock, as supported by lower serum lactate levels and less vasopressor requirements in the treated group [1]. However, the mortality rate in the treated group was lower than that in the usual care group, suggesting that this non-significant finding might be attributable to the limited sample size of the current study [1]. The authors describe the potential beneficial effects of anisodamine in detail, but do not mention the numerous side effects. Anisodamine, a tropane alkaloid extracted from the root of Anisodus tanguticus (Maxim.) Pascher in the family Solanaceae, acts as non-specific muscarinic cholinoceptor antagonist competing with acetylcholine for binding to the muscarinic cholinergic receptor, blocking nerve impulses and physiological functions associated with cholinergic neurotransmission [2]. The autonomic receptors distributed in the cardiac, vascular, and airway smooth muscle are mainly muscarinic cholinoceptors [2]. Thus, the antimuscarinic activity of anisodamine can potentially lead to various physiological effects on the cardiorespiratory system [2] and early experimental and clinical studies have indeed reported that structurally-related tropane alkaloids (such as anisodamine, anisodine, scopolamine, and atropine) have potentially undesirable effects on the particularly the cardiovascular systems [2], such as tachycardia and induction of arrhythmia [2] especially atrial arrhythmia [3]. Anisodamine is also know to increase the heart oxygen consumption and can cause torsade de pointes by increasing the QT interval [4]. Anisodamine induces coronary blood vessel dilation, increasing coronary blood flow, while also possibly inducing simultaneous elevation of the ventricular fibrillation threshold [5].
No takes yet. Share an insight, caveat, or question.
Honoré et al. (2021) conducted a letter in Septic shock (n=355). Anisodamine vs. Control was evaluated on Arrhythmias during treatment (p=0.627). Anisodamine treatment in patients with septic shock was associated with an 8.3% incidence of arrhythmias compared to 10.3% in the control group (p=0.627).
Synapse has enriched 10 related papers. Consider them for comparative context: